InsidersTradesSigma
Total declarations
Companies
▲ Purchases (11 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
11
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by Constantino Michael T., Directeur. Officer active across 2 companies, notably 9 METERS BIOPHARMA, INC.. In total, 12 disclosures have been recorded. Split: 11 buys · 0 sell. Total volume traded: €146k. History available since 24 August 2021. The latest transaction was disclosed on 7 April 2025 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Declarations12 total
16,000 shares@ US$1.2621.3% of flowCommon StockSEC:0001818382-25-000044:0
Ideal exit: 2 Jan 2026 (T+270)
4,600 shares@ US$4.387222.1% of flowCommon StockSEC:0001818382-24-000216:0
Ideal exit: 31 Aug 2025 (T+270)
3,100 shares@ US$6.288320.5% of flowCommon StockSEC:0001818382-24-000158:0
Ideal exit: 12 May 2025 (T+270)
4,750 shares@ US$4.1821.2% of flowCommon StockSEC:0001818382-23-000032:0
Ideal exit: 12 Feb 2024 (T+270)
7,885 sharesCommon StockSEC:0001578563-23-000011:0
2,000 shares@ US$4.8370.2% of flowCommon StockSEC:0001818382-22-000047:0
Ideal exit: 17 Feb 2023 (T+270)
16,000 shares@ US$0.475512.1% of flowCommon StockSEC:0001578563-22-000018:0
Ideal exit: 17 Feb 2023 (T+270)
26,508.74 shares@ US$0.754528.6% of flowCommon stockSEC:0001551986-22-000025:0
Ideal exit: 17 May 2021 (T+270)
200 shares@ US$10.832.2% of flowCommon StockSEC:0001104659-21-143251
Ideal exit: 19 Aug 2022 (T+270)
200 shares@ US$10.8314.9% of flowCommon StockSEC:0001104659-21-143251:0
Ideal exit: 19 Aug 2022 (T+270)
18,000 shares@ US$1.1429.6% of flowCommon stockSEC:0001551986-21-000099
Ideal exit: 21 May 2022 (T+270)
18,000 shares@ US$1.1429.6% of flowCommon stockSEC:0001551986-21-000099:0
Ideal exit: 21 May 2022 (T+270)
12 of 12 declarations
About Constantino Michael T.
Michael T. Constantino serves as a Board Member at 9 METERS BIOPHARMA, INC. and Humacyte, Inc. He contributes to the governance and strategy of both companies, bringing his expertise in the biopharmaceutical sector. With significant experience, he plays a key role in guiding strategic decisions and optimizing performance. His commitment to innovation and sustainability is essential for the boards.
